A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML

The response rate of non-M3 AML to all trans retinoic acid (ATRA) has been limited. Using Affymetrix expression arrays, we found that in diverse AML blasts RXRA was expressed at higher levels than RARA and that mouse Ctsg-PML-RARA leukemia responded to bexarotene, a ligand for RXRA. We therefore per...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Welch, John S., Niu, Haixia, Uy, Geoffrey L., Westervelt, Peter, Abboud, Camille N., Vij, Ravi, Stockerl-Goldstein, Keith E., Jacoby, Meagan, Pusic, Iskra, Schroeder, Mark A., Dipersio, John F., Cashen, Amanda F.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2014
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4108244/
https://ncbi.nlm.nih.gov/pubmed/24723466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23735
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items